Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07115485 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Name: Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma — clinical trial record (NCT07115485)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorShanghai Henlius Biotech

Started2025-09-15

View on ClinicalTrials.gov ↗

Amendment history

2025-11-14

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-08-20→confirmed 2025-09-15

Study sitesdetails revised at 1 of 1 site

2025-08-08

Original filing

Shanghai Henlius Biotech

56 trials monitored

See all monitored trials

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Details

NCT Number	NCT07115485
Lead Sponsor	Shanghai Henlius Biotech
Conditions	Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment	60 participants
Start Date	2025-09-15
Primary Completion	2027-08-30 (estimated)
Study Completion	2028-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-18